CDKN2A and exocrine pancreatic carcinoma: Taken together, at the moment it may be postulated that p14ARF promoter methylation is at least rarer than p16INK4a methylation in pancreatic carcinoma and that further evaluation of p14ARF's exact role in the development and course of pancreatic carcinoma requires further studies in greater patient cohorts, bringing together methylation data with functional findings.